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A B S T R A C T
Background: Increased thrombin formation and ﬁbrin deposition on the valves were observed in patients
with severe aortic valve stenosis (AS). Exercise enhances blood coagulation and ﬁbrinolysis in healthy
subjects, but its haemostatic effects in AS are unknown. We sought to investigate how stress
echocardiography alters blood coagulation and ﬁbrinolysis in AS patients free of signiﬁcant
atherosclerotic vascular disease.
Methods: We studied 32 consecutive asymptomatic moderate-to-severe AS patients and 32 age- and
sex-matched controls. We measured peak thrombin generated using calibrated automated thrombo-
gram, clot lysis time (CLT), and ﬁbrinolytic markers at four time points, i.e. at rest, at peak exercise, and
1 h and 24 h after a symptom-limited exercise test.
Results: We observed that peak thrombin generated rose at peak exercise to 25% higher value in the
patients than in controls (p < 0.001) and reached its highest level 24 h from exercise in AS patients while
it decreased post-exercise in controls. Baseline CLT was 13% longer in AS patients (p = 0.006) and
associated with thrombin activatable ﬁbrinolysis inhibitor (TAFI) activity (r = 0.69, p < 0.001),
antiplasmin (r = 0.47, p = 0.007), and plasminogen (r = 0.55, p = 0.001). In AS, CLT remained unaltered
at peak exercise, while it decreased in controls, yielding the intergroup difference of 28% (p < 0.001).
Twenty-four hours after exercise CLT became 15% longer in AS patients (p < 0.001). This hypoﬁbrinolytic
effect followed a similar pattern observed for TAFI activity.
Conclusions: Asymptomatic moderate-to-severe AS patients respond to exercise with more pronounced
and prolonged increase in thrombin generation, together with impaired ﬁbrinolysis as compared to
controls. Repeated episodes of exercise-induced prothrombotic state in AS might contribute to the
progression of this disease.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Aortic valve stenosis (AS) is the most common valvular heart
disease in adults, which could be asymptomatic for a long time [1].
Current evidence indicates that AS is an active process with
lipoprotein inﬁltration, chronic inﬂammation, extracellular matrix
remodeling, angiogenesis, and calcium deposition [2,3], which is to
some extent similar to atherosclerosis, in which enhanced blood
coagulation is involved in its progression and complications [4].* Corresponding author at: Institute of Cardiology, Jagiellonian University
Medical College, 80 Pradnicka St., 31-202 Krakow, Poland. Tel.: +48 12 6143004;
fax: +48 12 4233900.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsThere have been reports suggesting that AS is also associated with
enhanced blood clotting. Dimitrow et al. [5] have shown that there
is a prothrombotic state, characterized by increased thrombin
formation and platelet activation associated with maximal
transvalvular gradient in patients with severe AS. Altered
hemodynamic properties of blood ﬂow with the occurrence of
post-stenotic turbulence in AS can facilitate the activation of the
coagulation cascade with the resultant thrombin generation [5].
Microthrombi on the aortic valve have been shown in AS patients
[6]. It has been demonstrated that ﬁbrin accumulation occurs
within and on the surface of diseased valves in AS patients, and it is
associated with thrombin generation and ﬁbrin turnover in
circulating blood [7]. Moreover, tissue factor (TF) is abundantly
expressed in human stenotic aortic valves in association with
thrombin formation in circulating blood [8,9]. The loss of high reserved.
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to high shear stress lesion and vWF-mediated platelet dysfunction
can also be observed in patients with severe AS and predispose to
bleeding [10]. Recently, we have reported that hypoﬁbrinolysis is
more common in AS patients than in controls [11].
It is known that exercise can induce a prothrombotic state [12].
Beneﬁcial effects of physical activity on the risk of coronary artery
disease (CAD) and cardiovascular mortality may result at least in
part from increased ﬁbrinolysis following exercise [12,13]. To our
knowledge, there have been no studies on the effect of exercise on
blood coagulation and ﬁbrinolysis in AS patients. The present study
was performed to evaluate potential differences in the hemostatic
response to exercise test in AS patients vs. controls.
Materials and methods
Patients
Thirty-three consecutive adult patients with asymptomatic
moderate-to-severe AS [deﬁned as transvalvular maximal velocity
(Vmax) 3 m/s] were recruited from March 2011 to June 2012.
The exclusion criteria were: history of angina, dizziness,
syncope, another cardiac valve disease of more than a moderate
degree, left ventricular (LV) ejection fraction (EF) <50%, history of
or current atrial ﬁbrillation, hyper- or hypothyroidism, diabetes
treated with insulin, renal or hepatic dysfunction, lung disease,
oral anticoagulant therapy, use of thienopyridine or nonsteroidal
anti-inﬂammatory drugs other than aspirin, known cancer,
bleeding tendency, autoimmune disorders, a history of myocar-
dial infarction, stroke, or venous thromboembolism. Patients who
were not able to perform exercise testing were also excluded from
the study. Sex- and age-matched individuals recruited from the
families of hospital personnel served as controls. The study
protocol was approved by the University Bioethical Committee,
and each patient provided written, informed consent to partici-
pate in the study.
To evaluate the extent of atherosclerotic vascular disease,
which coexists in about 50% of AS patients [14], we measured
intima–media thickness (IMT) in both right and left common
carotid artery in accordance with the Mannheim IMT consensus
[15]. The ankle brachial pressure index (ABI) was measured using
an arterial pressure sphygmomanometer and a continuous wave
Doppler ultrasound blood ﬂow detector and values of 0.9–1.15
were considered normal. Hypertension was diagnosed based on a
history of hypertension or antihypertensive treatment. Hyperlip-
idemia was diagnosed based on medical records, statin therapy, or
total cholesterol of 5.0 mmol/L.
Echocardiography
Transthoracic echocardiography was performed in all enrolled
subjects using Philips iE33 (Philips Electronics, Andover, MA, USA).
LV volumes and EF were measured by the biplane Simpson’s
method. The aortic valve area (AVA) was calculated using the
standard continuity equation. Vmax, peak pressure gradient (PPG),
and mean pressure gradient (MPG) were calculated using the
modiﬁed Bernoulli equation.
A symptom-limited exercise stress echocardiography was
performed on a bicycle ergometer (Ergoline, Bitz, Germany) in a
semisupine position with a continuous echocardiographic exami-
nation by an experienced cardiologist. After 3 min of the initial
workload of 25 W, the workload was increased every 3 min by 25 W
[16]. Electrocardiogram was monitored and blood pressure was
measured every 3 min during exercise. Exercise was stopped in case
of typical chest pain, breathlessness, dizziness, muscular exhaus-
tion, hypotension, ventricular arrhythmia, when age-relatedmaximum heart rate was reached, or on the patient’s demand.
The test was performed at rest and peak exercise.
Laboratory tests
Fasting blood samples were drawn from the antecubital vein
between 07.00 h and 10.00 h. Fibrinogen was measured by the von
Clauss method. High-sensitivity C-reactive protein was deter-
mined using immunoturbidimetry (Roche Diagnostics, Mannheim,
Germany). Blood samples to determine hemostatic parameters
were drawn four times: at rest, at peak exercise, and 1 h and 24 h
after exercise and then centrifuged at 2500  g at 20 8C for 10 min
and stored at 80 8C until analysis. Technicians were blinded to the
origin of the samples.
Thrombin generation
Measurement of the thrombin endogenous potential was
performed using calibrated automated thrombography (Thrombi-
noscope BV, Maastricht, Netherlands) according to the manufac-
turer’s instructions in the 96-well plate ﬂuorometer (Ascent Reader,
Thermolabsystems OY, Helsinki, Finland). Eighty microliters of
platelet-poor plasma was diluted with 20 mL of the reagent
containing 5 pmol/L recombinant TF, 4 mM phosphatidylserine/
phosphatidylcholine/phosphatidylethanolamine vesicle, and 20 mL
of FluCa solution (HEPES, pH 7.35, 100 nmol/L CaCl2, 60 mg/mL
bovine albumin, and 2.5 mmol/L Z-Gly-Gly-Arg-AMC). Samples
were analyzed in duplicate; intra-assay variability was 5.7%. We
analyzed the maximum concentration of thrombin generated.
Endothelial cell activation markers
Plasma soluble thrombomodulin (TM) (Diagnostica Stago,
Asnie´res, France) and tissue plasminogen activator (tPA) antigen
(Hyphen BioMed, Neuville-Sur-Oise, France) were determined by
enzyme-linked immunosorbent assays (ELISA).
Fibrinolysis
Measurement of thrombin activatable ﬁbrinolysis inhibitor
(TAFI) antigen was performed with an ELISA (Chromogenix,
Lexington, MA, USA). The activity levels of plasminogen activator
inhibitor-1 (PAI-1) and TAFI were measured using a chromogenic
assay (Chromolize PAI-1, Trinity Biotech, Bray, County Wicklow,
Ireland; and ACTICHROME1 Plasma TAFI Activity Kit, American
Diagnostica, Greenwich, CT, USA, respectively).
PAI-1 antigen was determined in citrated plasma using
commercially available ELISAs according to the manufacturer’s
instructions (American Diagnostica).
Plasminogen and a2-antiplasmin (a2-AP) were measured by
chromogenic assays (Diagnostica Stago).
Plasma D-dimer was determined by immunoturbidimetry
(Innovance D-dimer, Siemens, Erlangen, Germany). Intra-assay
and inter-assay coefﬁcients of variation were <8%.
Clot lysis time (CLT) was measured as previously described [17]
with some modiﬁcations. Brieﬂy, citrated plasma was mixed with
Tris buffer (1:1) containing 15 mmol/L calcium chloride, 0.6 pmol/
L human TF (Innovin, Siemens, Marburg, Germany), 12 mmol/L
phospholipid vesicles (Avanti Polar Lipids, Alabaster, AL, USA), and
60 ng/mL recombinant tPA (Boerhinger Ingelheim, Ingelheim,
Germany). Turbidity was measured at 405 nm at 37 8C. CLT was
deﬁned as the time from the midpoint of the clear-to-maximum-
turbid transition, which represents the clot formation, to the
midpoint of the maximum-turbid-to-clear transition, representing
the lysis of the clot. Intra-assay and inter-assay coefﬁcients of
variation were 6.0 and 7.4%, respectively.
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Statistical analysis was performed using STATISTICA 10 PL
software package (StatSoft, Tulsa, OK, USA). Values are presented
as a mean  standard deviation or median or otherwise stated. The
Shapiro–Wilk test was performed to determine normal distribution of
the variables. The Student’s t test was used to determine differences
among normally distributed variables and the Mann–Whitney U test
for non-normally distributed variables. Serial tests were analyzed
using Freidman ranks analysis of variance. A linear Pearson
correlation was used to assess correlations among variables. A p-
value <0.05 was considered statistically signiﬁcant.
Results
Subject characteristics
Thirty-two AS patients and 32 controls were included in the ﬁnal
analysis (Table 1) due to the fact that one subject from each group
was excluded since elevated blood white cell count and hypothy-
roidism were observed in the respective subjects. Slightly lower
hematocrit, hemoglobin, platelet count, and more common
hypercholesterolemia were observed in AS patients, while other
routine laboratory parameters were similar in both groups (Table 1).
Echocardiography parameters
The indices of the AS severity were: Vmax = 3.8  0.59 m/s;
PPG = 59.4  19.8 mmHg; MPG = 35.4  14.1 mmHg; AVA = 1.08
 0.23 cm2; AVA indexed to body surface area (AVA/
BSA) = 0.58  0.1 cm2/m2. Bicuspid aortic valves were found in 12
(37.5%) AS patients.Table 1
Baseline characteristics.
AS patients
(n = 32)
Controls
(n = 32)
p
Males, n (%) 15 (46.8) 17 (53.1) 0.62
Age (years) 64 (23–82) 63.5 (33–83) 0.81
Body mass index (kg/m2) 30 (21–37) 28 (21–39) 0.19
Current smoking, n (%) 2 (6.2) 2 (6.2) 1.0
Hypertension, n (%) 26 (81.2) 27 (84.3) 0.74
Diabetes, n (%) 7 (21.8) 4 (12.5) 0.32
Hypercholesterolemia, n (%) 12 (37.5) 2 (6.2) 0.02
Laboratory investigations
Hemoglobin (g/dL) 13.5 (11.5–15.9) 14.6 (12.2–16.9) 0.003
Hematocrit (%) 40.7  2.8 42.7  2.7 0.002
Platelets (103/mL) 202 (127–356) 225 (142–325) 0.04
Fibrinogen (g/L) 3.26  0.7 3.04  0.5 0.21
Total cholesterol (mM) 5.03  1.04 5.26  1.2 0.41
LDL cholesterol (mM) 3.04  0.8 3.33  1.0 0.24
HDL cholesterol (mM) 1.48  0.3 1.48  0.4 0.92
Triglycerides (mM) 1.15 (0.4–4.2) 1.15 (0.4–2.3) 0.50
Glucose (mM) 5.85  1.1 5.38  0.5 0.30
Creatinine (mM) 73.8  12.4 77.3  13.9 0.28
C-reactive protein (mg/L) 1.23 (0.3–10.4) 1.6 (0.2–8.0) 0.61
Treatment
Aspirin, n (%) 18 (56.2) 10 (31.2) 0.044
Statins, n (%) 23 (71.8) 20 (62.5) 0.42
b-Blockers, n (%) 19 (59.3) 12 (37.5) 0.08
ACEI, n (%) 12 (37.5) 15 (46.8) 0.45
Vascular ultrasound examination
IMT (mm) 0.70  0.20 0.71  0.15 0.41
ABI 1.00  0.11 1.05  0.14 0.08
Data are median (interquartile range) or mean  SD, unless otherwise stated. p-
Value was measured using Student’s t-test when variables were normally
distributed or by the Mann–Whitney U test for non-normally distributed variables.
AS, aortic valve stenosis; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; ACEI, angiotensin-converting enzyme inhibitor; IMT, intima–media
thickness; ABI, ankle brachial pressure index.The duration of stress test was shorter in AS group (p = 0.008)
and maximum workload was lower (p = 0.002) and reached
81.3  21.1 W. During stress test seven (21.8%) patients had dyspnea
and three (9.3%) had angina without echocardiographic signs of
ischemia in AS patients, while in the control group ﬁve patients had
dyspnea (15.6%). In the AS group at maximum workload PPG rose to
75.3  26.1 mmHg, MPG to 45.3  15.9 mmHg, and EF to 73  6.5%
(all p < 0.05). There was no intergroup difference in post-exercise
increase in EF.
Thrombin generation
As shown in Fig. 1A and Table 2, peak thrombin generated
during peak workload in AS group increased by 25% (p < 0.001)
and was higher than in controls (p < 0.001). Interestingly, peak
thrombin generated in AS patients reached its peak 24 h after
exercise, while it followed a different pattern in controls, i.e. it
decreased reaching its nadir 24 h post-exercise (p < 0.001). There
was a positive correlation between peak thrombin generated at
baseline and left atrium volume (r = 0.42, p = 0.014), but not with
other echocardiographic parameters at any time point (data not
shown).
Fibrinolysis
As shown in Fig. 1B and Table 2, baseline CLT was 13% longer
among AS patients (p = 0.006) compared with controls. CLT
remained unaltered at peak exercise in AS group and it decreased
in controls (intergroup difference of 28%, p < 0.001). One hour after
exercise test CLT decreased in AS patients to a level similar to the
control group, and then increased 24 h later, being 15% higher than
in controls (p < 0.001). Exercise showed no effect on D-dimer in
either group (Table 2).
TAFI antigen remained unaltered during stress test in the AS
group. The only intergroup difference was observed at peak
exercise where TAFI antigen was slightly higher in the patients
(p = 0.015) (Table 2). In controls TAFI antigen was reduced at peak
exercise (p = 0.005) and 1 h after exercise compared to the baseline
value (p = 0.030). Interestingly, at all four time points, TAFI activity
was higher in AS group than in controls (all p < 0.001, Fig. 1C). In AS
patients, TAFI activity remained unaltered at peak exercise, but
then after a decrease after 1 h it rose above the baseline value
(p = 0.003). In controls, TAFI activity was reduced during the test
and after its completion compared to the baseline (all p < 0.01,
Fig. 1C). Of note there was a weak association between TAFI
antigen and Vmax (r = 0.36, p = 0.042).
Plasminogen was similar at baseline in both groups, but then it
was higher in AS group (all p < 0.05, respectively) (Table 2). There
were no differences in PAI-1 antigen between the two groups at
any time point. Although a2-AP remained unaltered during
exercise test in the AS group, it was higher than in the controls
at baseline (p = 0.024), similar at peak exercise, and lower at 1 and
24 h post-exercise (both p < 0.05, Table 2). Importantly, in AS
patients CLT at baseline, but not at the three other time points,
correlated with TAFI activity (r = 0.69, p < 0.001), a2-AP (r = 0.47,
p = 0.007), and plasminogen (r = 0.55, p = 0.001). In controls, CLT
correlated with TAFI activity at all time points (at rest: r = 0.65,
p < 0.001; at peak exercise: r = 0.54, p = 0.001; 1 h post-exercise:
r = 0.42, p = 0.015; 24 h post-exercise: r = 0.50, p = 0.003).
Other parameters
Soluble TM in both groups at baseline was similar, but it was
higher than in the control group both at peak exercise (p < 0.001),
1 h (p < 0.001), and 24 h after exercise (p = 0.034) (Fig. 1D and
Table 2). Pre-exercise CLT correlated with TM in the AS group
Fig. 1. Exercise-induced changes during symptom-limited exercise on a bicycle ergometer in 32 asymptomatic aortic valve stenosis patients (AS) and 32 well-matched
controls (C) in: (A) peak thrombin generated; (B) clot lysis time (CLT); (C) thrombin activatable ﬁbrinolysis inhibitor activity (TAFI); (D) thrombomodulin (TM). Panel I shows
absolute values (data are presented as a mean  SD); Panel II shows percentage changes of the parameters measured in speciﬁc time periods: from pre-exercise to peak exercise;
from peak exercise to 1 h post-exercise, and from 1 h to 24 h post-exercise (baseline – 0% represents their initial, pre-exercise value).
Table 2
Markers of blood coagulation and ﬁbrinolysis at baseline, peak exercise, and 1 and 24 h after exercise.
Time point AS patients (n = 32) Controls (n = 32) p
Peak thrombin generated (pg/mL) Pre-exercise 247  62.0 229  37.7 0.26
Peak exercise 309  65.1 253  41.9 <0.001
1 h post-exercise 291  58.6 235  51.2 <0.001
24 h post-exercise 320  50.9 219  38.2 <0.001
CLT (min) Pre-exercise 104  18.2 92  12.9 0.006
Peak exercise 112  16.4 87  15.0 <0.001
1 h post-exercise 72  12.2 71  12.7 0.47
24 h post-exercise 110  13.0 95  11.8 <0.001
TAFI activity (mg/mL) Pre-exercise 35  7.7 28.6  6.4 <0.001
Peak exercise 36  7.1 26  4.8 <0.001
1 h post-exercise 30  5.1 23  4.6 <0.001
24 h post-exercise 37  7.5 25  4.6 <0.001
TAFI antigen (%) Pre-exercise 103  10.4 105  10.3 0.38
Peak exercise 106  12.8 99  8.9 0.015
1 h post-exercise 105  12.2 100  9.6 0.08
24 h post-exercise 106  11.2 103  10.1 0.23
PAI-1 (ng/mL) Pre-exercise 51  25.2 55  19.8 0.64
Peak exercise 51  21.1 57  16.2 0.22
1 h post-exercise 48  19.3 46  17.6 0.44
24 h post-exercise 47  19.8 47  18.1 0.92
Plasminogen (%) Pre-exercise 101  12.3 99  10.8 0.69
Peak exercise 97  15.6 88  10.2 0.023
1 h post-exercise 110  13.3 91  14.9 <0.001
24 h post-exercise 106  27.3 90  15.2 0.019
a2-AP (%) Pre-exercise 106  12.0 99  10.4 0.024
Peak exercise 104  15.8 108  11.6 0.10
1 h post-exercise 99  15.6 108  11.1 0.011
24 h post-exercise 99  14.0 108  11.7 0.008
tPA antigen (ng/mL) Pre-exercise 4.8  1.8 4.3  1.2 0.39
Peak exercise 5.1  2.3 5.6  2.1 0.37
1 h post-exercise 3.7  1.4 3.6  1.2 0.96
24 h post-exercise 3.7  1.6 3.4  1.1 0.56
TM (ng/mL) Pre-exercise 3.8  1.6 3.9  1.8 0.83
Peak exercise 4.0  2.1 2.4  1.2 <0.001
1 h post-exercise 3.7  1.3 2.3  1.2 <0.001
24 h post-exercise 3.8  1.4 3.2  1.2 0.034
D-Dimer (ng/mL) Pre-exercise 432  309 441  235 0.51
Peak exercise 619  629 477  300 0.84
1 h post-exercise 491  425 543  393 0.51
24 h post-exercise 585  650 549  520 0.92
Data are given as mean  SD. p-Value was determined using Student’s t-test.
AS, aortic valve stenosis; CLT, clot lysis time; TAFI, thrombin activatable ﬁbrinolysis inhibitor; PAI-1, plasminogen activator inhibitor-1; a2-AP, a2-antiplasmin; tPA, tissue
plasminogen activator; TM, thrombomodulin.
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between the AS and control groups (data not shown).
Subgroup analysis
Subgroups of AS patients were identiﬁed based on: (1) stroke
volume indexed to body surface area <35 mL/m2 and  35 mL/m2
(15 vs 17 patients); (2) exercise-induced elevation of MPG
>20 mmHg and 20 mmHg (27 vs 5 patients); (3) exercise-
induced increase in LVEF 10% and <10% (21 vs 11 patients). The
only signiﬁcant difference was observed in the peak thrombin
generated at 24 h post-exercise (330.2  48.1 pg/mL in the sub-
group with MPG elevation 20 mmHg vs 268.6  38.1 pg/mL in the
subgroup with MPG elevation >20 mmHg, p = 0.010).
Discussion
The study is the ﬁrst to demonstrate that during exercise stress
testing moderate-to-severe AS patients show a speciﬁc pattern of
prothrombotic changes in coagulation and ﬁbrinolysis markers,
which is different from that observed in age- and sex-matched
controls. Our control group does not consist of healthy subjects,
however this sample is representative of the population in this age
range. Even in patients with a normal stress test, we observed
exercise-induced greater increase in maximum concentration of
thrombin generated combined with lower ﬁbrinolysis and those
alterations were detectable even 24 h after the test. Of note, those
alterations cannot be attributable to signiﬁcant atherosclerotic
vascular disease. Our ﬁndings could suggest that unlike in
individuals free of AS and/or CAD, physical exercise in asymptom-
atic AS patients can produce unfavorable effects, which might
predispose to faster progression of AS as suggested recently [11].
Our observations apply to patients with moderate-to-severe AS,
and cannot possibly be extended to the early stages of this disease.
Thrombin generation
There have been few studies on blood coagulation in AS that
reported enhanced thrombin generation using a different meth-
odology [5,18]. Most likely, at rest increased thrombin formation
can be detected in symptomatic patients with severe AS and/or
with concomitant CAD. Furthermore, we measured the peak
thrombin generated, a reliable marker of a prothrombotic state
[19], which has not been tested in AS until now. We observed
increased peak thrombin generated, not only at peak exercise but
even 24 h after exercise in AS patients, while in controls there was
a modest increase in the peak thrombin generated at peak exercise,
and its decrease 24 h post-exercise. These results in AS patients are
different from those observed in healthy young male subjects in
whom no changes in endogenous thrombin potential during
exercise were observed [20]. Clear differences in the proﬁle of
thrombin potential during exercise in AS patients and the controls
suggest that regulatory mechanisms of blood coagulation leading
to a quick return to baseline values after the exercise test are
impaired in AS. The mechanisms behind this observation are
unknown and probably several mechanisms might be implicated.
It has been postulated that AS and atherosclerosis are similar
diseases. Despite a different location, the main interface appears to
be the vascular endothelium. Flow turbulence at the supravalvular
region in AS patients, increasing during exercise, can cause
disruption of the endothelium followed by a local proinﬂamma-
tory, prothrombotic, and procoagulant state. Furthermore, there is
evidence that reduced blood volume may activate thrombin
generation [21]. The stroke volume is decreased in AS patients.
Higher heart rate during exercise may compensate lower cardiac
output among healthy individuals, whereas in AS cardiac output islower at an increased heart rate due to the wall stiffness, resulting
in the diastolic function impairment. Reduced stroke volume,
followed by reduced blood volume, might contribute to pro-
thrombotic alterations during exercise in AS patients. It has been
also suggested that hemolysis of red blood cells enhances blood
coagulation [22]. Intravascular hemolysis related to AS has been
reported in a few case reports regarding AS patients [23,24].
However, in a randomly selected subgroup of our AS patients we
failed to observe any laboratory indices of hemolysis (Kolasa-Trela,
unpublished data). It has been established that thrombin itself can
cause endothelial cell perturbation [4], thus hypercoagulability
observed in AS may cause further destruction of the valve leaﬂets.
It remains to be established why natural anticoagulant systems,
including protein C and antithrombin, cannot quickly shut down
the burst of exercise-induced thrombin generation in asymptom-
atic moderate-to-severe AS.
Fibrinolysis
We observed impaired ﬁbrinolysis in AS patients prior to the
exercise test, reﬂected by prolonged CLT, which is in accordance
with a recent study by Natorska et al. [11]. A novel ﬁnding is that
exercise-induced acceleration of ﬁbrinolysis in AS patients is
delayed and transitory as compared to the alterations observed in
controls. Interestingly, while CLT shortened in controls at peak
exercise, it remained on the same level among AS individuals. We
found that shortening of CLT in AS was delayed (1 h post-exercise)
and transitory (it was prolonged again 24 h after exercise). The
observed ﬁbrinolytic plasma proﬁle in AS cannot be explained by
the diurnal variation of ﬁbrinolytic activity because of intergroup
differences. A different pattern of change in ﬁbrinolytic potential
during exercise in AS also varied from that observed in patients
with hypertension, in whom increased coagulation parameters
were accompanied by enhanced ﬁbrinolysis [25]. Mechanisms of
this observation could be related to TAFI which represents a link
between the blood coagulation and ﬁbrinolysis. Unexpectedly, we
found that the initial TAFI activity was higher in AS and positively
associated with CLT. One of the possible explanations of elevated
pre-exercise TAFI activity levels are observations that TAFI has an
anti-inﬂammatory effect through inactivation of anaphylatoxin
C5a, thrombin-cleaved osteopontin, and bradykinin [26]. A similar
positive association between TAFI and CLT has been reported in
patients with cardiovascular disease and those with venous
thrombosis [26–28]. To the best of our knowledge, this study is
the ﬁrst to demonstrate that increased TAFI could contribute to
hypoﬁbrinolysis in AS. In the AS group TAFI remained at the same
level until it transiently decreased 1 h after exercise to re-increase
beyond its initial value 24 h after exercise, while in controls TAFI
activity levels decreased permanently since peak exercise and
were lower than in AS at all time points. In AS patients we did not
observe any exercise-related changes in TAFI antigen. In control
group TAFI antigen decreased, which is in accordance with another
study [29]. Methods that utilize antibodies speciﬁc for TAFI antigen
quantify overall TAFI consumption and/or TAFI generation, and
cannot measure the level of TAFI activity. Quantifying the extent of
TAFI activation is a more precise diagnostic marker in thrombotic
diseases [26]. Considering a similar proﬁle in post-exercise
changes in TAFI activity and CLT among AS patients (Fig. 1B and
C), it could be presumed that elevated TAFI activity is largely
responsible for delayed and transitory hyperﬁbrinolytic response
in this disease. We observed slightly lower PAI-1 after exercise
among controls and no alteration in AS patients, which indicates
that this inhibitor does not contribute to altered pattern of CLT
changes during exercise test. The data on post-exercise changes in
plasma PAI-1 are inconsistent [30], but most of them showed a
neutral effect [29]. It has to be underscored that since patients with
R. Kolasa-Trela et al. / Journal of Cardiology 65 (2015) 501–507506documented CAD, carotid artery stenosis, and peripheral artery
disease were excluded, concomitant advanced atherosclerosis,
known to be associated with prolonged CLT [31], cannot explain
attenuated ﬁbrinolytic response to exercise in our AS group.
Interestingly, our data indicate that intense exercise does not
positively affect hemostasis in moderate-to-severe AS patients.
If indeed exercise-induced prothrombotic alterations in circu-
lating blood are clinically relevant, such prothrombotic pheno-
type might be an additional argument for earlier surgical
treatment. This concept merits validation in a large prospective
study.
Endothelial cell activation
A proﬁle of changes in soluble TM in AS, which has been
reported here for the ﬁrst time, deserves a comment. We found
that TM remained unchanged in AS during and after exercise, while
it decreased in the current age-matched controls; in healthy
individuals most studies showed no exercise-related changes of
TM levels [32,33]. TM is involved both in the suppression of
thrombin generation and impairment of ﬁbrinolysis via activation
of TAFI. Rapid turbulent blood ﬂow in valve stenosis can damage
endothelial cells lining the ascending aorta [31] which results in
increased shedding of TM from the endothelium. Sustained high
TM levels could be involved in unaltered TAFI levels post-exercise
in AS.
Study limitations
Both study groups were small, however their size was sufﬁcient
to show the intergroup differences in ﬁbrinolytic parameters. Our
ﬁndings cannot be likely extrapolated to the whole population of
AS patients since the study participants with mild or symptomatic
AS were excluded. The patients studied had no bleeding tendency
and multimers of vWF were not measured, therefore the impact of
exercise test on this parameter remains to be established. Follow-
up larger studies are needed to assess the risk of cardiovascular
events in AS and their links with disturbed hemostasis. This issue
was beyond the scope of the present study.
Conclusions
In conclusion, our results indicate that asymptomatic patients
with moderate or severe AS respond to physical activity with a
marked increase in endogenous thrombin potential and sup-
pressed ﬁbrinolytic capacity compared with controls. The present
data combined with previous observations [11] suggest that
exercise-induced prothrombotic alterations in AS patients may
promote ﬁbrin deposition on aortic valve leaﬂets, leading to the
progression of this disease. It might be speculated that intense
exercise could contribute to faster progression of valvular lesions
and higher risk of cardiovascular events. The potential clinical
relevance of altered hemostasis in AS warrants further investiga-
tion.
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